Light Horse Therapeutics, a San Diego, CA-based developer of small molecule therapeutics, raised $62M in Series A funding.
The round was led by Versant Ventures and included Mubadala Capital as well as Bristol-Myers Squibb Co, Taiho Ventures, and AbbVie.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Markus Renschler, Light Horse has developed a proprietary platform that uncovers novel functional sites in disease-critical targets. The company integrated approaches to build this precision genetic editing-based platform that interrogates proteins in their native environment, providing a better discovery of clinical candidates.
Its technology turns conventional drug discovery on its head by first identifying novel functional domains and then screening for chemistry. This function-first approach is the converse of traditional screening-first methodologies.
The team also includes:
- Thomas Daniel, MD, Chairman
- Laure Escoubet, PhD, CSO
- Brian Liau, PhD, scientific co-founder
- Ben Cravatt, PhD, scientific co-founder
- Nathanael Gray, PhD, scientific co-founder
FinSMEs
10/01/2025